10 Oversold Biotech Stocks to Buy Now

5. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Relative Strength Index (RSI): 38.51

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands fifth on our list of oversold biotech stocks to buy now and is a biopharmaceutical company that develops RNA interference (RNAi) therapies to treat rare genetic diseases. Its medicines, including ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRA, target and silence specific genes that cause conditions like hereditary ATTR amyloidosis and acute hepatic porphyria.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported strong financial growth in its Q4 2024 results. The company’s total net product revenue for 2024 reached $1.646 billion, a 33% increase from 2023. Its TTR franchise generated $343 million in Q4, reflecting 35% year-over-year growth, while full-year TTR revenue in the U.S. rose to $705 million, a 39% increase. Notably, the company achieved a non-GAAP operating income of $95 million, marking its first profitable year.

The company’s success highlights its ability to commercialize RNAi therapeutics effectively. The recent positive results from the HELIOS-B Phase III study for vutrisiran in ATTR cardiomyopathy have led to global regulatory filings, potentially expanding its market. This could significantly grow Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s presence in the ATTR amyloidosis space.

Looking ahead, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) expects 2025 product sales between $2.05 billion and $2.25 billion, with TTR revenue projected at $1.6 billion to $1.725 billion, assuming AMVUTTRA is approved for ATTR cardiomyopathy. The company also anticipates growth in its rare disease franchise.